Jim Hoffman: Thrombomodulin as a Key Regulator of Coagulation and Inflammation
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared a post on LinkedIn about an article by Yasuyo Shimomura et al. published in Journal of Intensive Care, adding:
“Thrombomodulin (TM) is a protein that plays a crucial role in regulating coagulation and inflammation.
It is primarily expressed on the cell surface of endothelial cells, but its soluble form exists in the circulation as well.
TM, when optimally dosed, has been demonstrated to exert a protective effect against greater endothelial dysfunction and vascular damage during experimental sepsis and coagulopathy.
Recombinant human-soluble TM (rTM) administration has been used in humans, primarily in Japan, for the treatment of sepsis and hematological malignancy-associated disseminated intravascular coagulation DIC, reducing the severity of vascular injury since 2008.
In the context of dysregulated NETosis, which is also prevalent DIC progression, resulting in greater vascular injury, TM is known to inhibit platelet and LPS-facilitated NETosis induction in vitro.
Based on the work of Toh et al., and the enlightening research of many other NETosis investigators; NETosis dysregulation should be directly targeted by extracorporeal depletion therapy to reduce DIC severity and reduce the risk of life-threatening immunothrombotic ischemic events.
NETosis induction and impaired chromatin/NET clearance from the blood positively correlate with an increased risk of life-threatening disseminated intravascular coagulation and ischemic circulatory failure events.”
Title: Recombinant human thrombomodulin inhibits neutrophil extracellular trap formation in vitro
Authors: Yasuyo Shimomura, Mika Suga, Naohide Kuriyama, Tomoyuki Nakamura, Toshikazu Sakai, Yu Kato, Yoshitaka Hara, Chizuru Yamashita, Hiroshi Nagasaki, Masao Kaneki, Osamu Nishida

Stay updated on all scientific advances Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support